Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera

Journal article

SARS-CoV-2 has caused over 2 million deaths in little over a year. Vaccines are being deployed at scale, aiming to generate responses against the virus spike. The scale of the pandemic and error-prone virus replication is leading to the appearance of mutant viruses and potentially escape from antibody responses. Variant B.1.1.7, now dominant in the UK, with increased transmission, harbors 9 amino acid changes in the spike, including N501Y in the ACE2 interacting surface. We examine the ability of B.1.1.7 to evade antibody responses elicited by natural SARS-CoV-2 infection or vaccination. We map the impact of N501Y by structure/function analysis of a large panel of well-characterized monoclonal antibodies. B.1.1.7 is harder to neutralize than parental virus, compromising neutralization by some members of a major class of public antibodies through light-chain contacts with residue 501. However, widespread escape from monoclonal antibodies or antibody responses generated by natural infection or vaccination was not observed.

Authors: Supasa, P; Zhou, D; Dejnirattisai, W; Liu, C; Mentzer, AJ

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Cell Press
• Journal: Cell
• Volume: 184
• Issue: 8
• Pages: 2201-2211.E7
• Publication date: 2021-02-18
• Acceptance date: 2021-02-13
• DOI: 10.1016/j.cell.2021.02.033
• EISSN: 1097-4172
• ISSN: 0092-8674
• Language: English
• Keywords: FFR; variant; IGHV3-53; SARS-CoV-2; escape; neutralization; B.1.1.7; Kent; antibody